ARGXargenxSigning up patients
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
AChR-Ab Seropositive Generalized Myasthenia Gravis · Myasthenia Gravis · MG · gMG · Generalized Myasthenia Gravis · Generalized Myasthenia Gravis (gMG)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 70 (planned)
- Started
- Dec 19, 2025
- Main results expected
- Mar 7, 2028
- Fully finished
- Mar 7, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of adverse events and serious adverse events in parts A and B
Measured over: Up to 21 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07284420 · record last updated 2026-09-24 · checked 2026-11-09 15:47 UTC